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Background: Most African countries have adopted artemisinin-based combination therapy (ACT) as the first-line
treatment for uncomplicated malaria. The World Health Organization now recommends limiting anti-malarial
treatment to those with a positive malaria test result. Limited data exist on how these policies have affected ACT
prescription practices.
Methods: Data were collected from all outpatients presenting to six public health facilities in Uganda as part of a
sentinel site malaria surveillance programme. Training in case management, encouragement of laboratory-based
diagnosis of malaria, and regular feedback were provided. Data for this report include patients with laboratory
confirmed malaria who were prescribed anti-malarial therapy over a two-year period. Patient visits were analysed in
two groups: those considered ACT candidates (defined as uncomplicated malaria with no referral for admission in
patients ≥ 4 months of age and ≥ 5 kg in weight) and those who may not have been ACT candidates. Associations
between variables of interest and failure to prescribe ACT to patients who were ACT candidates were estimated
using multivariable logistic regression.
Results: A total of 51,355 patient visits were included in the analysis and 46,265 (90.1%) were classified as ACT
candidates. In the ACT candidate group, 94.5% were correctly prescribed ACT. Artemether-lumefantrine made up
97.3% of ACT prescribed. There were significant differences across the sites in the proportion of patients for whom
there was a failure to prescribe ACT, ranging from 3.0-9.3%. Young children and woman of childbearing age had
higher odds of failure to receive an ACT prescription. Among patients who may not have been ACT candidates, the
proportion prescribed quinine versus ACT differed based on if the patient had severe malaria or was referred for
admission (93.4% vs 6.5%) or was below age or weight cutoffs for ACT (41.4% vs 57.2%).
Conclusions: High rates of compliance with recommended ACT use can be achieved in resource-limited settings.
The unique health facility-based malaria surveillance system operating at these clinical sites may provide a
framework for improving appropriate ACT use at other sites in sub-Saharan Africa.
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In 2001 the World Health Organization (WHO) recom-
mended artemisinin-based combination therapy (ACT)
for the treatment of uncomplicated Plasmodium falcip-
arum malaria in countries with resistance to older mo-
notherapies [1]. At the time ACT was neither widely
available nor affordable in many countries with limited re-
sources. Five years later, 41 African countries (and 65
worldwide) had adopted ACT as first-line therapy and 21
were deploying ACT at public health facilities [2]. In 2010,
WHO expanded its recommendations to include labora-
tory confirmation with microscopy or a rapid diagnostic
test (RDT) before initiating anti-malarial therapy [3]. The
use of ACT based on laboratory confirmation represents a
dramatic shift in malaria case management in Africa fol-
lowing decades of largely empiric therapy with inexpen-
sive, older monotherapies. Currently, limited data exist on
recent anti-malarial prescription practices in Africa fol-
lowing these changes. In Kenya, where case management
practices have been published following a policy change
promoting universal parasitological diagnosis before treat-
ment, a majority of patients were not getting diagnostic
testing or treatment according to test result, although
those with positive tests and uncomplicated malaria did
receive recommended treatment with artemether-lume-
fantrine (AL) in 90% of cases when AL was available [4].
Uganda, which has some of the highest rates of malaria
transmission in the world [5,6], adopted ACT in 2004
and began deployment in early 2006 [7]. AL was selected
as the first-line therapy for uncomplicated malaria and
artesunate plus amodiaquine was recommended as an
alternative first-line therapy. Oral quinine was recom-
mended as second-line therapy for uncomplicated mal-
aria and parenteral quinine remained first-line therapy
for complicated malaria [8,9]. In 2006, training was
conducted throughout the country with the goal of edu-
cating all front-line clinicians on the new treatment pol-
icy [10]. Job aids and clinical guidelines were also
distributed at the health facilities. In Uganda, clinical
consultation, laboratory testing, and medications are pro-
vided free of charge at all public health facilities.
In 2006, with support from the U.S. President’s Malaria
Initiative (PMI), a unique sentinel site malaria surveillance
programme was established at six public health facilities
in Uganda. As described previously, this programme was
successful in reaching a 97% laboratory testing rate for
patients with suspected malaria and fewer than 10% of pa-
tients with a negative laboratory test were prescribed anti-
malarial therapy [11]. The purpose of this report is to
describe anti-malarial prescription practices among outpa-
tients with laboratory-confirmed malaria and to identify
factors associated with inappropriate therapy. A better un-
derstanding of how Uganda’s change in malaria treatment
policy has translated into practice in the setting of anactive training and surveillance programme is vital to im-
proving the appropriate use of anti-malarial therapy.
Methods
Health facility-based malaria surveillance system
The Uganda Malaria Surveillance Project (UMSP) is a
collaboration between Makerere University, the Uganda
Ministry of Health, the London School of Hygiene and
Tropical Medicine, and the University of California San
Francisco. In 2006 UMSP, working with the Uganda
National Malaria Control Programme (NMCP), created a
health facility-based malaria surveillance system at six
sentinel sites throughout the country, the details of which
have been described previously [11,12]. Briefly, these fa-
cilities are level IV government-run health centers which
primarily provide outpatient services, have catchment po-
pulations of approximately 100,000 people, and were se-
lected to represent a range of settings with respect to
malaria epidemiology (Figure 1). Most patients are treated
by clinical officers, but medical officers, nurses, and mid-
wives may also evaluate patients. Each site has a pharmacy
and a laboratory with capacity to perform microscopy.
There are also approximately 10–15 inpatient beds, which
may be utilized for brief admissions, although this capacity
is not available at two of the sites (Kasambya and
Walukuba).
Individual-level data are collected for each outpatient
who presents to the health facility using a standardized
case record form (CRF) completed by the clinicians during
the patient encounter (Additional file 1). Data collected
include demographics, malaria laboratory test results (mi-
croscopy or RDT), diagnoses (including uncomplicated
malaria, severe malaria, or malaria in pregnancy), medica-
tions prescribed and dispensed, and disposition. Suspected
malaria is defined as all patients referred for malaria la-
boratory testing plus all patients not referred for a malaria
laboratory test but given a clinical diagnosis of malaria.
The dosing of each medication and the route of adminis-
tration is not recorded.
Supply of anti-malarial medications
Most medications are purchased by the Ministry of
Health with government funds and financial support
from the Global Fund for AIDS, Tuberculosis and Mal-
aria (GFATM). International donors have also made rela-
tively smaller quantities of anti-malarials available. At the
start of the study the Uganda National Medical Stores dis-
tributed medications to each district every two months
based on the amount of medication requested by the dis-
trict [9]. The district would then distribute the medica-
tions to the health facilities. In mid-2011, due to frequent
stock-outs, the National Medical Stores began distributing
medications directly to the health facilities. For level IV
health facilities the amount of medication delivered was
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Figure 1 Location of sentinel site malaria surveillance programme health facilities.
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Ministry of Health has also worked with non-govern-
mental partners to improve forecasting of stock-outs and
to streamline the anti-malarial supply chain. These efforts
have led to substantial reductions in anti-malarial stock-
outs [13]. Notably, the supply of anti-malarials is not
influenced by UMSP staff.
Sentinel site health care worker training and other support
Following the initiation of the malaria surveillance pro-
gramme in 2006, 118 clinicians from the six sentinel sites
and three additional sites underwent a six-day training
designed to promote a high-quality team-based approach
to fever case management. Clinical training involved lec-
tures and simulated case-based training centered on the
Uganda Ministry of Health malaria treatment guidelines
as previously described [14,15]. Following the initial train-
ing programme, the sentinel sites were visited by the
UMSP staff every 1–2 months to provide feedback on case
management, share data, and ensure the supply of labora-
tory materials. From 2011 to 2012, site visits were spaced
out to every 4–6 months.Statistical analysis
Data collected over a 2-year period from January 2011
through December 2012 were included in this study. Only
patients with laboratory-confirmed malaria, documented
prescription of an anti-malarial, and documented age
were included in the analysis. Patients recorded as being
pregnant were excluded as the surveillance system does
not reliably capture the trimester of pregnancy and thus it
was not possible to classify these patients based on their
candidacy for ACT. For analysis, study participants were
placed into two groups based on whether or not it was
thought they were candidates for ACT in accordance with
national malaria treatment guidelines. Those who were
considered candidates for ACT were given a diagnosis of
uncomplicated malaria, were four months of age or older,
were 5 kg in weight or above, and were not referred for
admission. Those who were not clear candidates for ACT
were either given a diagnosis of severe malaria, referred
for admission, less than four months of age, or had a
weight recorded as <5 kg.
Statistical analysis was performed using Stata 12.0
(Stata Corp, College Station, TX). Associations between
Outpatient visits













confirmed malaria prescribed any





Figure 2 Selection of patient visits included in the analysis.
Sears et al. Malaria Journal 2013, 12:252 Page 4 of 9
http://www.malariajournal.com/content/12/1/252variables of interest and inappropriate anti-malarial ther-
apy among patients in the ACT candidate group were es-
timated using logistic regression. Variables of interest
included clinical site, age, whether or not the patient was
a woman of child-bearing age (15 to 49 years), concur-
rent prescription of antibiotics, and transmission season
(where high transmission season was defined as the
months at each clinical site where the malaria test posi-
tivity rate is above the mean for that site and low trans-
mission season comprised the remaining months).
Results
Study population and characteristics
During the study period a total of 290,253 outpatient
visits were recorded (Figure 2). Malaria was suspected in
58.4% of all outpatient visits (range 38.5-74.6% across the
sites). Among patients with suspected malaria, 98.0%
underwent diagnostic testing. Among those who under-
went diagnostic testing, only 3.2% had an RDT performed,
with over 93% of RDTs performed at two sites (Kasambya
and Kamwezi). Of all patients who underwent diagnostic
testing, 32.0% had laboratory-confirmed malaria (range
23.8-38.9% across the sites). Within the group of patients
with laboratory-confirmed malaria, 3.3% were excluded
from the final analyses: 2.0% were reported to be pregnant,
1.3% had no prescribed anti-malarial drugs recorded,
and <0.1% had no age recorded. Of note, among patients
who were reported to be pregnant, 54% were prescribed
ACT, 45% were prescribed quinine, and 1% were pre-
scribed other anti-malarials.
Characteristics of the 51,355 outpatient visits included
in the final study population are described in Table 1. The
proportion of patients <5 years of age ranged from 20.8%
in Kamwezi to 63.8% in Nagongera. The study population
showed a slight female predominance, which was consist-
ent across sites. Overall 19.6% of patients were women of
childbearing age (range 11.6-24.0% across the sites). The
concurrent prescription of antibiotics with anti-malarials
was recorded in 29.1% of patients, ranging from 10.2% in
Kamwezi to 55.7% in Aduku.
Prescription practices among ACT candidates
Considering all patient visits included in the final ana-
lyses with laboratory-confirmed malaria who were pre-
scribed an anti-malarial, 90.1% were considered to be
candidates for ACT, ranging from 72.8% in Nagongera
to 99.5% in Walukuba (Table 2). ACT candidates were
appropriately prescribed ACT at 94.5% of visits. Among
patients who were prescribed ACT, 97.3% were prescribed
the first-line regimen AL (n = 42,537). The remaining pa-
tients were prescribed artemisinin-naphthoquine (AN, n
= 870, 2.0%), dihydroartemisinin-piperaquine (DP, n = 326,
0.7%), and a single patient was prescribed artesunate plus
sulphadoxine-pyrimethamine (SP). Over 90% of AN pres-criptions and over 95% of DP prescriptions originated
from single sites (Kasambya and Kamwezi respectively). Of
note, no patients were prescribed artesunate plus amo-
diaquine, which is considered an alternative first-line regi-
men in Uganda. When AL was prescribed, it was recorded
as dispensed by the pharmacy at 92.0% of visits in 2011
and 99.0% of visits in 2012. Other forms of ACT were dis-
pensed after prescription at 99.0% of visits.
Table 1 Characteristics of the study population
Variable All Sites Aduku Kamwezi Kasambya Kihihi Nagongera Walukuba
Patient visits, n (% total) 51,355 4,489 (8.7%) 5,241 (10.2%) 11,227 (21.9%) 9,076 (17.7%) 8,880 (17.3%) 12,442 (24.2%)
Age in years, median (IQRa) 8 (2.6-20) 9 (2.4-23) 12 (5.0-23) 10 (3.0-22) 8 (3.5-17) 2.5 (1.2-10) 11 (3.8-24)
Female gender, n (%) 29,025 (56.5%) 2,583 (57.5%) 2,794 (53.3%) 6,426 (57.2%) 5,160 (56.9%) 4,842 (54.5%) 7,220 (58.0%)
Women of childbearing ageb, n (%) 10,050 (19.6%) 1,078 (24.0%) 1,159 (22.1%) 2,332 (20.8%) 1,594 (17.6%) 1,031 (11.6%) 2,856 (23.0%)
Prescribed antibiotics, n (%) 14,966 (29.1%) 2,500 (55.7%) 534 (10.2%) 5,163 (46.0%) 2,422 (26.7%) 1,744 (19.6%) 2,603 (20.9%)
During high transmission seasonc, n (%) 30,435 (59.3%) 2,629 (58.6%) 3,142 (60.0%) 6,469 (57.6%) 5,123 (56.5%) 5,220 (58.8%) 7,852 (63.1%)
a Inter-quartile range.
b 15-49 years of age.
c High transmission season: any month where the test positivity rate is above the mean test positivity rate for the site.
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fied as ACT candidates but were not prescribed ACT, anti-
malarials prescribed included quinine (n = 2,396, 94.7%),
artemether (n = 128, 5.1%), chloroquine plus SP (n = 3,
0.1%), chloroquine (n = 2, <0.1%), artesunate (n = 1, <0.1%)
and SP (n = 1, <0.1%). Associations between variables of
interest and failure to prescribe ACT are presented in
Table 3. The proportions of patients classified as ACT can-
didates but not prescribed ACT ranged from 3.0% in
Aduku to 9.3% in Nagongera. Compared to Aduku, the
other sites had significantly higher odds of not prescribing
ACT after controlling for other variables, with odds ratios
ranging from 1.43 (95% CI 1.16-1.76) in Walukuba to 2.60
(95% CI 2.12-3.20) in Nagongera. Decreasing age was asso-
ciated with increasing odds of not being prescribed ACT.
Patients 4 months to <2 years of age had over four times
the odds of not being prescribed ACT (OR = 4.69, 95% CI
4.10-5.37) compared to patients 10 years of age or older
after controlling for other variables. Women of childbea-
ring age had higher odds of not being prescribed ACT
(OR = 1.79, 95% CI 1.54-2.07). Patients who were pre-
scribed antibiotics had lower odds of not being prescribed
ACT (OR = 0.89, 95% CI 0.81-0.98). There was no signifi-
cant association between malaria transmission season and
the failure to prescribe ACT.
Prescription practices among patients who may not have
been ACT candidates
Of the 5,090 patients who may not have been candidates
for ACT, 92.7% were classified as such due to being given
a diagnosis of severe malaria or referred for admission
(Table 2). The remaining patients were below the recom-
mend age or weight requirements for administration ofTable 2 Classification of candidacy for ACT by clinical site
Candidacy for ACT All Sites Aduku K
Candidate for ACT, n (%) 46,265 (90.1%) 4,039 (90.0%) 4,9
May not be candidate for ACT, n (%) 5,090 (9.9%) 450 (10.0%) 26
Severe malaria or referred for admission 4,716 390
Age <4 months or weight <5 kg 374 60ACT. Among sites with access to onsite inpatient facilities,
the proportion of patients that were given a diagnosis of
severe malaria or referred for admission ranged from 4.7%
in Kamwezi (where 20.8% of study patients were under
five years-old) to 26.0% in Nagongera (where 63.8% of
study patients were under five years-old). In contrast, at
the two sites that lacked access to onsite inpatient facilities
(Kasambya and Walukuba), less than 1% of patients were
given a diagnosis of severe malaria or referred for admis-
sion. Prescribing practices for the study participants who
may not have been candidates for ACT differed based on
their reason for inclusion in the non-ACTgroup (Figure 3).
Those given a diagnosis of severe malaria or referred for
admission were most frequently prescribed quinine
(93.4%), followed by ACT (6.5%). Children below the age
of four months or under 5 kg in weight were prescribed
quinine less frequently than ACT (41.4% vs 57.2%). In both
groups the ACT prescribed was nearly always AL (n = 512,
98.7%), while a minority of patients received prescriptions
for DP (n = 5, 1.0%) and AN (n = 2, 0.4%). There were five
patients across the two groups who were prescribed arte-
misinin monotherapies (artemether = 4, artesunate = 1)
and four who were prescribed non-ACT (chloroquine = 3,
SP = 1). When quinine was prescribed it was recorded as
dispensed at 90.4% of visits in 2011 and 97.0% of visits in
2012. ACT was dispensed after prescription at 89.5% of
visits in 2011 and 97.8% of visits in 2012.
Discussion
Changes in malaria case management advocated by
WHO, including the use of ACT and treatment based on
laboratory confirmation, have the potential to efficiently
reduce the burden of malaria in Africa where healthamwezi Kasambya Kihihi Nagongera Walukuba
81 (95.0%) 11,127 (99.1%) 7,274 (80.2%) 6,464 (72.8%) 12,380 (99.5%)
0 (5.0%) 100 (0.9%) 1,802 (19.9%) 2,416 (27.2%) 62 (0.5%)
247 8 1,760 2,305 6
13 92 42 111 56






OR (95% CI) p-value OR (95% CI) p-value
Clinical site Aduku 3.0% 1.0 (reference) - 1.0 (reference) -
Walukuba 4.1% 1.41 (1.15-1.73) 0.001 1.43 (1.16-1.76) 0.001
Kamwezi 4.2% 1.46 (1.16-1.83) 0.001 1.68 (1.34-2.13) <0.001
Kihihi 5.6% 1.96 (1.59-2.41) <0.001 2.11 (1.71-2.61) <0.001
Kasambya 6.2% 2.17 (1.78-2.64) <0.001 2.24 (1.83-2.73) <0.001
Nagongera 9.3% 3.36 (2.75-4.11) <0.001 2.60 (2.12-3.20) <0.001
Age ≥10 years 3.1% 1.0 (reference) - 1.0 (reference) -
≥5 years and <10 years 5.3% 1.71 (1.51-1.93) <0.001 2.19 (1.89-2.54) <0.001
≥2 years and <5 years 7.9% 2.63 (2.35-2.93) <0.001 3.33 (2.90-3.82) <0.001
≥4 months and <2 years 11.0% 3.80 (3.43-4.23) <0.001 4.69 (4.10-5.37) <0.001
Women of childbearing agea No 5.8% 1.0 (reference) - 1.0 (reference) -
Yes 4.2% 0.70 (0.63-0.78) <0.001 1.79 (1.54-2.07) <0.001
Prescribed antibiotics No 5.5% 1.0 (reference) - 1.0 (reference) -
Yes 5.4% 0.98 (0.90-1.07) 0.674 0.89 (0.81-0.98) 0.017
Transmission season Low 5.3% 1.0 (reference) - 1.0 (reference) -
High 5.6% 1.04 (0.96-1.13) 0.302 1.08 (0.99-1.17) 0.084
aWomen 15 to 49 years old.
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all malaria suspects received a diagnostic test and 94.5% of
ACT candidates were prescribed ACT for laboratory-
confirmed malaria, demonstrate that high rates of appro-
priate malaria case management can be achieved in
outpatient settings. Much of this success is likely due to
the unique health facility-based malaria surveillance sys-
tem, which included an additional training programme for
clinicians and periodic feedback sessions where data were
shared and progress toward meeting case management
goals was tracked. The impressive rates of appropriate
ACT use at these sites is especially vital given theFigure 3 Prescription practices among patients who may not have beextraordinarily high burden of malaria in Uganda and the
excellent efficacy of ACT when used for uncomplicated
malaria in the country [16-21].
Not only was the decision to use ACT frequently ap-
propriate, but nearly all patients prescribed ACT were
prescribed AL, the recommended first-line therapy for
uncomplicated malaria in Uganda. Artesunate plus amo-
diaquine, the alternate first-line therapy for uncompli-
cated malaria, was not prescribed during the study
period and is not procured by the Uganda Ministry of
Health. AN and DP, which comprised all but one of the
remaining forms of ACT prescribed, were used aten ACT candidates.
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of these medications had been made available by
international donors during the study period. Further en-
couraging was the fact that stock-outs were rare as
pharmacy-dispensing records indicated that 91.5% of pre-
scribed anti-malarials were dispensed by the pharmacy in
2011 and 98.7% were dispensed in 2012. The rise in the
proportion of anti-malarials dispensed from 2011 to 2012
is likely in large part due to changes in how medications
were delivered to the health centers. Beginning in mid-
2011 the National Medical Stores began directly delivering
medications to the level IV health centers (bypassing the
district health team) as part of a comprehensive effort to
streamline the supply chain. This system has reduced the
frequency of stock-outs being reported by the health facil-
ities [13]. Improved data collection during this time period
may also explain some of the rise in the proportion of
anti-malarials dispensed as pharmacy practices were first
incorporated into the surveillance system in January of
2011 and the proportion of records missing this informa-
tion declined from 4.3% in 2011 to 1.1% in 2012.
The translation of ACT policy to ACT prescribing
practices has been difficult in many African countries
where rates of appropriate ACT use has ranged from
22% to 76% [22-29]. One study in Kenya did show that
AL was prescribed to 90% of patients with uncomplicated
laboratory-confirmed malaria when data were limited to
health facilities with both AL and diagnostic testing in
stock [4]. Various barriers to ACT adoption have been
cited, including low numbers of clinicians with advanced
degrees and inadequate provider training which often fo-
cused on in-service lectures and dissemination of written
guidelines without chart audits, feedback, and follow-up
training. Stock outs have also been shown to be a barrier
to appropriate anti-malarial prescription practices in sub-
Saharan Africa [30] and the low rates of stock outs at the
facilities presented in this study may have contributed to
the high rates of ACT use. These results stand in contrast
to early reviews of data from selected health facilities in
Uganda, which reported difficulty in achieving high rates
of compliance with the new ACT treatment policy in the
setting of frequent stock outs. A study done one year
after the rollout of AL showed that AL was prescribed in
only 60% of outpatient fever cases when it was indicated
per national guidelines [10]. A single health facility study
did, however, report rates as high as 89% during this
same time-frame [31]. Also in contrast to the results
presented here, neither of these studies reported high
rates of diagnostic testing prior to anti-malarial prescrip-
tion. The low utilization of malaria diagnostic testing ap-
pears to be common in Uganda as a national survey done
in 2011 revealed that only 32% of children under five
years of age had blood drawn when taken to a health fa-
cility for fever [32]. While an investigation using 2010data taken from the same sentinel sites reported here de-
scribed high rates of diagnostic testing, AL use was only
69% in outpatient laboratory-confirmed cases [11]. The
findings described in this report thus indicate substantial
improvement in ACT prescription practices at these sites
over the last two years.
Despite the high rate of appropriate ACT use in the
study, there is still a minority of ACT candidates who are
not prescribed ACT. The data presented here suggest
some variables associated with a failure to prescribe ACT
to an appropriate candidate, but why these associations
exist and what can be done to correct them will warrant
further investigation. Certain clinical sites, for example,
had higher rates of failure to appropriately prescribe ACT,
but the reason for this discrepancy is uncertain. One
Ugandan study noted a difference in prescribing practices
between nurses and clinical officers or physicians [31],
which could be a contributing factor in this study’s sites as
the composition of clinic staff is different at each site. Dif-
ferences in dissemination of training and local anti-ma-
larial prescribing culture at each clinic may also be playing
a role. The finding that younger children were at higher
risk of being prescribed non-ACT when they were ACT
candidates is surprising and also merits further study.
Given the excellent efficacy and side effect profile of these
medications, coupled with the increased vulnerability of
young children to complications of malaria, correcting this
practice will be of great importance. Additionally, women
of childbearing age who are not pregnant should be pre-
scribed ACT for uncomplicated malaria, yet multivariable
analysis reveals that this group is at increased risk of not
receiving ACT. This finding suggests that providers may
be avoiding ACT out of fear that the patient might be or
will soon become pregnant, a practice that is not endorsed
by the Ugandan malaria treatment guidelines. Improved
diagnosis of early pregnancy and additional ACT training
interventions will be needed to target this remaining defi-
ciency as well. Finally, the finding that those who were
prescribed antibiotics were more likely to be prescribed
ACT is surprising. It is not clear why this association ex-
ists and further studies will be needed to better under-
stand this practice.
Among the patients who were not clear candidates for
ACT, the proportion of patients with severe malaria or
referral for admission who were prescribed quinine was
very high (93.4%). Administration of quinine to these pa-
tients would be consistent with Ugandan malaria treat-
ment guidelines assuming these patients did indeed have
severe malaria. There was one subgroup of patients, how-
ever, who received therapy outside of national guidelines
at high rates – those who were below age or weight
criteria for ACT. These patients received a prescription
for ACT more often than they received a prescription
for quinine. Making providers aware of the weight and
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imperative.
There are several limitations to this study. The sentinel
surveillance sites in Uganda are unique clinical settings
where laboratory confirmation of malaria is common, thus
limiting the generalizability of the findings. Also limiting
generalizability is the fact that many patients do not seek
treatment at public clinics, choosing instead to rely on pri-
vate clinics, private pharmacies, and traditional healers
[32,33]. Additionally, the classification of candidacy for
ACT is dependent on the clinical judgment and documen-
tation of the clinicians as well as the decision to admit the
patient. These are all imperfect markers for identifying se-
vere malaria. Finally, the data collected indicate what anti-
malarial is prescribed and dispensed by the pharmacy but
not the dosing of the medication, the route of administra-
tion, or the patient’s adherence to the prescribed regimen.
While a single study showed that AL is usually dosed cor-
rectly in Uganda [10], reports on the adherence of Ugan-
dans to anti-malarials have varied substantially [34-36] and
no conclusions on dosing, route of administration, or ad-
herence can be drawn from this study.Conclusions
More than six years after Uganda rolled out ACT as the
first-line therapy for uncomplicated malaria, prescription
practices show very high rates of compliance with
recommended ACT use across six outpatient sites with
high rates of malaria diagnostic testing and an improved
supply chain of anti-malarials. The unique health facility-
based malaria surveillance system operating at these clin-
ical sites—which has provided additional clinical training,
feedback on case management, and sharing of data col-
lected from the sites—is likely a crucial component of the
high rates of appropriate ACT use. Such improvements in
clinical training and feedback may serve as a model for
improving compliance with guidelines for ACT use at
other sites in sub-Saharan Africa.Additional file
Additional file 1: Case record form. Standardized form used to collect
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